Headlines

Dry Eye Treatment to Be Acquired in $5.3B Deal

The deal is expected to close later this year.

Published

2 years ago

May 10, 2019

Novartis announced that it will acquire Xiidra 5%, a dry eye treatment, from Takeda Pharmaceutical Co. Ltd. in a deal worth up to $5.3 billion.

Xiidra (lifitegrast ophthalmic solution) is described in a press release as “the first and only prescription treatment approved to treat both signs and symptoms of dry eye by inhibiting inflammation caused by the disease.”

INVISION Podcast

What’s Really Up with Vision Expo in 2021?

INVISION Podcast

Podcast: Talking with the Finest, Hippest of Them All About Why There are No Ball Point Pens in Her Shop

INVISION Podcast

Licensed or Not, Member or Not, the Opticians Association of America is Here for You [Podcast]

“Xiidra, with its unique dual benefits, is an example of the type of innovative advances we invest in for the benefit of patients,” said Paul Hudson, CEO of Novartis Pharmaceuticals.

“We look forward to leveraging our well-established commercial infrastructure to bring this medicine to more patients.”

Deal terms include a $3.4 billion upfront payment with potential milestone payments of up to $1.9 billion. Novartis will be taking on about 400 employees associated with the product.

Closing of the transaction is expected in the second half of 2019, subject to customary closing conditions, including regulatory approvals.

Transform Your Multi-office Phone System Into a Revenue-generation Tool

Weave’s multi-office, multi-department, and multi-provider phone system is built to flexibly accommodate and augment your practices’ most powerful revenue-generation tool: ring phones across multiple locations, set up inter-office call overflow, support external call centers, and more. And by connecting to your patient data, call handlers see a patient’s upcoming appointments, overdue balances, overdue family members, and preferred location – all when they pick up the phone." Learn more at getweave.com/weave-unify